gvtcx

Provision of Assay Kits for SCID & SMA In-Service Evaluations - EONIS-Q Revvity

NHS England Published 12 Mar 2026 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£4,074,117
Statuscomplete
Category (CPV) 33100000
Deadline12 Mar 2026
Contract start1 Apr 2026
Contract end31 Mar 2029
Procedureselective
SME suitableYes
OCIDocds-b5fd17-63bc49a4-6875-44ee-bcf1-d9ea348f4445

Award

SupplierValueDateStatus
Revvity (UK) Limited £4,074,117 25 Mar 2026 active

description

EONIS-Q Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) in 4 Screening laboratories, with the addition of the ISE for Spinal Muscular Atrophy (SMA).

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
12 Mar 2026 Award (award) · d1d6ec3d-8b57-42c2-bcc9-988c98df5b88-888234

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.